Revenue for Arexvy and Abrysvo fell sharply year over year in the fourth quarter due to narrower U.S. guidelines for their ...

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

the FDA noted. RSV is a major cause of hospitalization among older adults, particularly those aged older than 75 years. The shots made by GSK and Pfizer were the first RSV vaccines ever approved ...

After approval ... risk in adults ages 50 and older vaccinated with Arexvy. The FDA further determined that the benefits of vaccination with the two RSV vaccines continue to outweigh their ...

The FDA will require GSK and Pfizer to include on the label of their respiratory syncytial virus (RSV) vaccines ... of which were approved by the agency in May of 2023 for adults 60 years or ...

Getting FDA approval is just the first ... in the US in adults aged 65 years and older each year. The scale of the problem has led analysts to predict that the market for RSV vaccines could ...

The FDA has approved Pfizer’s respiratory syncytial virus (RSV) vaccine for older adults, just a few weeks after a rival shot from GSK became the first to ... reviewing their safety and efficacy ...

For older adults ... from the virus for the first six months of life. The FDA has approved three RSV vaccines for preventing ...

One Zelienople child survived a serious health scare after coming down with respiratory syncytial virus in late January. The ...

Moderna is down 80% from its 52-week high as revenues continue to fall and the new RSV vaccine ... approval for mRESVIA if for adults ages 60 and up. GSK's Arexvy already has FDA approval in the ...